Qian Jiang1,2, Hai-Bo Wang3, Lu Yu4, Robert Peter Gale5. 1. Peking University People's Hospital, Peking University Institute of Hematology, No. 11 Xizhimen South Street, Beijing, 100044, People's Republic of China. jiangqian@medmail.com.cn. 2. Collaborative Innovation Center of Hematology, Soochow University, Suzhou, People's Republic of China. jiangqian@medmail.com.cn. 3. Peking University Clinical Research Institute, Beijing, People's Republic of China. 4. Peking University People's Hospital, Peking University Institute of Hematology, No. 11 Xizhimen South Street, Beijing, 100044, People's Republic of China. 5. Division of Experimental Medicine, Department of Medicine, Hematology Research Centre, Imperial College London, London, UK.
Abstract
PURPOSE: Explore patient-reported outcomes (PROs), including health-related quality of life (HRQoL), satisfaction with therapy, impact of the therapy on work and daily life, and concerns related to the therapy and identify variables associated with PROs in persons with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitors (TKIs). METHODS: Across-sectional questionnaire was distributed to adults with chronic phase CML and answered anonymously. SF-36 Health Survey was used to measure HRQoL. Our focus was on the physical component summary (PCS) and mental component summary (MCS) components. RESULTS: Data from 819 respondents receiving TKI-therapy ≥3 months and achieving a complete cytogenetic response were analyzed. Median age was 42 years (range 18-88 years). 652 (80%) were receiving imatinib. Median TKI-therapy duration was 36 months (range 3-178 months). 629 (77%) paid some or all of their TKI costs. In multivariate analyses, female sex, increasing age, lower education level, increasing co-morbidities, concomitant medication, ≥3 symptoms, moderate or severe symptom, switch from imatinib to a second-generation TKI, and higher annual out-of-pocket expense of TKI were significantly associated with lower PCS and/or MCS. However, TKI-therapy duration 3-7 years was significantly associated with better well-being. Higher PCS or MCS score was significantly associated with higher satisfaction level with TKI-therapy and less impact of TKI-therapy on subject's daily life and work. In addition, adverse impact on daily life and work was significantly associated with more interests in TKI-therapy-related issues. CONCLUSIONS: Social-economic and clinical variables were significantly associated with PROs in persons with CML receiving TKI-therapy.
PURPOSE: Explore patient-reported outcomes (PROs), including health-related quality of life (HRQoL), satisfaction with therapy, impact of the therapy on work and daily life, and concerns related to the therapy and identify variables associated with PROs in persons with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitors (TKIs). METHODS: Across-sectional questionnaire was distributed to adults with chronic phase CML and answered anonymously. SF-36 Health Survey was used to measure HRQoL. Our focus was on the physical component summary (PCS) and mental component summary (MCS) components. RESULTS: Data from 819 respondents receiving TKI-therapy ≥3 months and achieving a complete cytogenetic response were analyzed. Median age was 42 years (range 18-88 years). 652 (80%) were receiving imatinib. Median TKI-therapy duration was 36 months (range 3-178 months). 629 (77%) paid some or all of their TKI costs. In multivariate analyses, female sex, increasing age, lower education level, increasing co-morbidities, concomitant medication, ≥3 symptoms, moderate or severe symptom, switch from imatinib to a second-generation TKI, and higher annual out-of-pocket expense of TKI were significantly associated with lower PCS and/or MCS. However, TKI-therapy duration 3-7 years was significantly associated with better well-being. Higher PCS or MCS score was significantly associated with higher satisfaction level with TKI-therapy and less impact of TKI-therapy on subject's daily life and work. In addition, adverse impact on daily life and work was significantly associated with more interests in TKI-therapy-related issues. CONCLUSIONS: Social-economic and clinical variables were significantly associated with PROs in persons with CML receiving TKI-therapy.
Authors: Carlo Gambacorti-Passerini; Laura Antolini; François-Xavier Mahon; Francois Guilhot; Michael Deininger; Carmen Fava; Arnon Nagler; Chiara Maria Della Casa; Enrica Morra; Elisabetta Abruzzese; Anna D'Emilio; Fabio Stagno; Philipp le Coutre; Rafael Hurtado-Monroy; Valeria Santini; Bruno Martino; Fabrizio Pane; Andrea Piccin; Pilar Giraldo; Sarit Assouline; Muheez A Durosinmi; Onno Leeksma; Enrico Maria Pogliani; Miriam Puttini; Eunjung Jang; Josy Reiffers; Maria Grazia Valsecchi; Dong-Wook Kim Journal: J Natl Cancer Inst Date: 2011-03-21 Impact factor: 13.506
Authors: Annie Guérin; Lei Chen; Raluca Ionescu-Ittu; Maryna Marynchenko; Roy Nitulescu; Robert Hiscock; Christopher Keir; Eric Qiong Wu Journal: Curr Med Res Opin Date: 2014-08-05 Impact factor: 2.580
Authors: Jorge E Cortes; Jeffrey H Lipton; Carole B Miller; Lambert Busque; Luke P Akard; Javier Pinilla-Ibarz; Christopher Keir; Ghulam Warsi; Felice P Lin; Michael J Mauro Journal: Clin Lymphoma Myeloma Leuk Date: 2016-02-16
Authors: Ishan Hirji; Shaloo Gupta; Amir Goren; Diana R Chirovsky; Alyson B Moadel; Eduardo Olavarria; Timothy W Victor; Catherine C Davis Journal: Health Qual Life Outcomes Date: 2013-10-08 Impact factor: 3.186
Authors: Ruben A Mesa; Carole B Miller; Maureen Thyne; James Mangan; Sara Goldberger; Salman Fazal; Xiaomei Ma; Wendy Wilson; Dilan C Paranagama; David G Dubinski; Ahmad Naim; Shreekant Parasuraman; John Boyle; John O Mascarenhas Journal: Cancer Date: 2016-09-30 Impact factor: 6.860
Authors: Tim H Brümmendorf; Carlo Gambacorti-Passerini; Andrew G Bushmakin; Joseph C Cappelleri; Andrea Viqueira; Arlene Reisman; Susanne Isfort; Carla Mamolo Journal: Ann Hematol Date: 2020-04-19 Impact factor: 3.673